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 Asthma is a common disease that is most frequently treated with inhaled 
glucocorticoids which are used to decrease inflammation and mucus production in the 
airways.  However, about 30% of asthma patients do not respond to treatment.  A possible 
hypothesis for glucocorticoid insensitivity is increased metabolism of inhaled 
glucocorticoids by cytochrome P450 3A (CYP3A) enzymes, particularly in the lung.  The 
objectives for this dissertation were to evaluate the metabolism of five inhaled 
glucocorticoids (budesonide, beclomethasone dipropionate, fluticasone propionate, 
triamcinolone acetonide, and flunisolide) by CYP3A enzymes, and to determine if 
treatment with glucocorticoids in lung cells induced CYP3A enzyme expression, further 
increasing the metabolism of glucocorticoids in the lung.  All three CYP3A enzymes 
(CYP3A4, 3A5, and 3A7) metabolized the five glucocorticoids, but to varying degrees 
and with unique products.  CYP3A4 and CYP3A5 were the most efficient at metabolizing 
the glucocorticoids; CYP3A7 had the lowest rates of metabolism.  The most common 
metabolites produced by CYP3A enzymes with triamcinolone acetonide, budesonide, 
flunisolide, and beclomethasone dipropionate were 6β-hydroxylated and Δ6-
dehydrogenated product, all of which are believed to be clearance metabolites.  
Investigation into the metabolism of beclomethasone dipropionate by A549 lung cells 
showed that a dehydrogenated P450-mediated metabolite, [M5], was produced, decreasing 
bioavailability of the active drug.  It was also demonstrated that CYP3A5 mRNA was 
induced in A549 cells with glucocorticoid treatment.  The induction of CYP3A mRNA 
was blocked when cells were co treated with esterase inhibitors and BDP, confirming the 
active metabolite, beclomethasone 17-monopropionate ([M1]), was mediating the 
induction of CYP3A5 mRNA, presumably through the glucocorticoid receptor (GR).  
CYP3A5 mRNA induction was also attenuated by inhibiting GR using the antifungal 
drug, ketoconazole, further supporting the hypothesis that glucocorticoids binding to GR 
was the mechanism of CYP3A5 induction in A549 cells.  Additional experimentation with 
primary cells (NHBE, lobar, SAEC, BEAS-2B, and tracheal cells) demonstrated that only 
SAEC cells expressed CYP3A5.  However, CYP3A5 mRNA was not induced in SAEC 
cells with glucocorticoid treatment despite extensive manipulation of cell culture 
conditions, such as removing hydrocortisone and utilizing charcoal-stripped FBS for 
treatment, which could have interfered with the mechanism observed in A549 cells.  
Overall, the collective results described in this dissertation support the hypothesis that 
increased metabolism of glucocorticoids in the lung could lead to decreased 
bioavailability of pharmacologically active drug, and that continued treatment with 
inhaled glucocorticoids could perpetuate the inefficacy by inducing CYP3A5 enzymes, 
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Asthma is a disease characterized by chronic inflammation of the airways that 
includes bronchoconstriction, increased mucus production and occasional airway 
obstruction (1).  This disease accounts for an estimated 500,000 hospital visits per year (2) 
and in 2007 the National Heart, Lung, and Blood Institute estimated that asthma cost the 
United States of America $20 billion in lost productivity and healthcare cost (3).  The 
most alarming statistic was in 2009 when the Center for Disease Control estimated there 
were 24.6 million people with asthma in this country, with 7 million under the age of 18 
(4, 5).  From these data, it is evident that asthma directly and indirectly affects the entire 
U.S. population through increasing healthcare cost, loss of productivity, as well as having 
an enormous impact on the health of our pediatric and neonatal populations, which will 
continue to impact their health and livelihood throughout their lives. 
 
Asthma Is a Complex Disease 
Asthma is a complex disease because it has diverse genetic and environmental 
components.  Twin studies have shown a strong genetic component to asthma (6, 7), with 
heritability estimated to be from 35% - 95% (8-14).  Although inheritance does not follow 
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Mendelian genetics, it is commonly believed that multiple genes are responsible for 
asthma (15, 16).  Genetic studies have found over 120 genes associated with asthma, all of 
which can be grouped into mutations affecting the structural components of the airways, 
increased levels and/or aberrant regulation of inflammatory proteins, or a decrease in 
antiinflammatory proteins (17).   
Recent genome-wide association studies have implicated four loci that are 
consistently associated with asthma across different ethnicities; 17q21, 2q12, 5q22.1 and 
interleukin 33 (IL33) (15, 18).  These loci are all associated with an increase in the 
endogenous inflammatory response.  The first locus implicated in asthma susceptibility is 
the orosomucoid-like 3 gene/gadsdermin like gene (ORMCL3/GSDML) located on 
chromosome 17q21 (19).  This locus has been associated with early childhood onset of 
asthma, particularly in children with frequent exacerbations, respiratory viral infections, 
and exposure to tobacco smoke (20-22).  Interestingly, children that have one of the many 
single nucleotide polymorphisms (SNP) in this region do not have any asthma attacks 
associated with direct contact with known common allergens or atopy, but experience 
symptoms sporadically (23).  The functions of ORMCL3 and GSDML are still poorly 
understood, but SNPs are believed to decrease endoplasmic reticulum Ca2+, which results 
in an induced endogenous inflammatory response (24).  The second locus implicated in 
asthma susceptibility is interleukin 1 receptor-like 1/interleukin 18 receptor 1 gene 
(IL1RL1/IL18R1) located on chromosome 2q12 (25).  This locus has been implicated in 
atopic asthma patients comorbid and codes for the IL1RL1 receptor, which IL-33 binds to 
on mast cells, T helper 2 cells, T-regulatory cells, and macrophages (18).  This locus is 
most commonly seen in patients that have asthma attacks from multiple environmental 
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factors and requires vigilant control of their environments (no pets, no carpet, etc).  The 
third locus is TSLP (thymic stromal lymphopoietin) located on chromosome 5q22.1 (25).  
TSLP is an epithelial cell derived cytokine involved in the inflammatory process 
associated with asthma.  SNPs in this region have also been highly associated with food 
allergies (26). The fourth locus is IL33, which has been implicated in allergy induced 
asthma.  IL33 activates mast cells, T helper 2 cells, T-regulatory cells, and macrophages 
(18).  This locus has also been implicated in children requiring vigilant control of their 
environments.  Though these are the four most common loci associated with asthma, it has 
also been documented that children can be afflicted with asthma without having any 
family history of the disease (15), suggesting a strong environmental component. 
The most common environmental instigators of asthma are a severe allergic 
reaction to an airborne allergen, such as cigarette smoke or a pesticide, and exposure to a 
viral infection in infancy or early childhood, such as the paramyxovirus or the respiratory 
syncytial virus (27).  There is also been evidence to suggest that children born in winter 
months in colder regions of the world also have a higher incidence of asthma, possibly 
due to decreases in Vitamin D exposure (28). 
Asthma patients suffer most commonly from acute attacks brought on by an 
environmental trigger.  Some environmental triggers include dust mite exposure, exercise, 
pet dander, cigarette smoke inhalation, and air pollution (29).  Studies have also shown 
that there are genetic factors that predispose patients to having asthma symptoms when 
exposed to certain environmental triggers (30), meaning not every patient has an asthma 
attack when exposed to the same triggers as another patient.  This inherent variability in 
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patient susceptibility to triggers complicates studying the genetic basis for asthma, as well 
as diagnosis. 
 
Diagnosis of Asthma 
Symptoms of asthma include chest tightness, wheezing, and breathlessness that 
often occur several times in a day or week (31).  Asthma diagnosis begins with an 
extensive family history questionnaire and a  physical examination in which physicians 
evaluate hyperexpansion of the thorax, wheezing occurring during normal breathing and 
forced exhalation, increased nasal swelling, and a manifestation of any allergic skin 
condition, such as eczema (32).  Spirometry tests are then used to evaluate the maximal 
volume of air forcibly exhaled from maximal inhalation (FVC) and the volume of air 
exhaled during the first second of exhalation (FEV1) (32).  Ratios of FEV1/FVC before 
and after a short acting bronchodilator are used to determine how much obstruction is seen 
in patients and to determine if there is improvement or significant reversibility after a 
short acting bronchodilator (29, 32).  Significant reversibility is defined as > 200mL 
increase in FEV1 and a > 10% increase in FEV1/FVC ratio as compared to baseline (32).   
Severity of asthma is also divided into four categories upon diagnosis: intermittent, mild 
persistent, moderate persistent, and severe persistent (29).  Intermittent is defined as 
symptoms less than once per week with brief exacerbations.  Mild persistent is defined as 
symptoms more than twice a week, but less than once a day, and exacerbations affecting 
activity or sleep.  Moderate persistent is defined as daily symptoms with exacerbations 
affecting activity and sleep.  Severe persistent is defined as daily symptoms, with frequent 
exacerbations and frequent sleep exacerbations.  Defining severity of asthma aids the 
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physician in determining the most appropriate therapeutic paradigm based on 
recommendations from the National Heart, Lung, and Blood Institute (32).   
Diagnosis of asthma is difficult because many of the characteristic symptoms of 
asthma can also occur in other conditions and disease states, such as chronic obstructive 
pulmonary disease (COPD), tuberculosis, allergic rhinitis, and pneumothorax (18).  Chest 
x-rays may also be performed to rule out these disorders (32), but even after physical 
examination and performing the diagnostic procedures outlined above, patients are not 
considered to have asthma unless improvement is seen after a 2-3 week glucocorticoid 
treatment regiment (32).  However, this theory is flawed based on reports of patient 
insensitivity to glucocorticoid treatment (33), and persistent symptoms of asthma, lending 
to potential misdiagnosis of asthma.    
 
Inhaled Glucocorticoid Therapy 
The first-line treatment for asthma is glucocorticoid therapy (29, 32, 34).  These 
drugs work by activating the glucocorticoid receptor (GR) in the cytosol of bronchiolar 
lung cells, forming a steroid-receptor complex, which translocates to the nucleus, and 
decreases the expression of proinflammatory genes and mucus production pathways in the 
lung (35-38).  The five most common inhaled glucocorticoids used in the clinic are 
flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, and 
fluticasone propionate (32).  Clinical studies over the last two decades have compared the 
potency of these five drugs, and laboratories have ranked them as follows (least potent to 
most potent): flunisolide = triamcinolone acetonide < beclomethasone dipropionate (BDP) 
< budesonide < fluticasone propionate (38).  This ranking has been determined by 
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quantifying glucocorticoid receptor complex half-lives, glucocorticoid receptor binding 
affinities, and the topical potency skin blanching test (38), which measures the 
vasoconstriction of skin where steroids have been applied topically (39).   
 
Glucocorticoid Resistance 
Although glucocorticoids are the first-line treatment for chronic asthma, about 
30% of the asthmatic population does not respond to treatment due to glucocorticoid 
resistance or insensitivity (36).   Patients are defined as being resistant to steroids if they 
exhibit less than a 15% improvement in baseline FEV1 after a ten to fourteen day course 
of high dose steroids (40, 41).  Some factors contributing to steroid resistance are believed 
to be genetic abnormalities in the glucocorticoid receptor, abnormalities in histone 
acetylation, the ability of patients to control oxidative stress, and latent viral infections 
(41, 42).  However, the exact mechanisms of glucocorticoid resistance is still unknown 
(43).  A possible mechanism for resistance may be due to the differential metabolism and 
accelerated clearance of glucocorticoids in target cells and tissues by tissue-specific 
expression of catabolic enzymes, including cytochrome P450s.   
 
Cytochrome P450 Enzymes 
Cytochrome P450s (P450s) are heme-containing monooxygenases found in all 
organisms; Cyto stands for microsomal vesicles, chrome for colored, P for pigmented and 
450 for their characteristic absorbance at 450 nm when treated with a reductant and 
carbon monoxide (44-46).  They are biological catalysts that perform many different 
chemical reactions, such as oxidation of xenobiotics, and synthesis of steroids and 
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cholesterol (47-50).  Over 58 human P450 enzymes have been identified since their initial 
discovery in 1962 (45).  Table 1.1 summarizes all human cytochrome P450 enzymes 
identified to date, their tissue distribution, and their ability to metabolize glucocorticoids 
(51-61).  Cytochrome P450 enzymes are expressed predominately in the liver, but are also 
expressed in other such as the kidney, lung, brain, intestine, pancreas, bone marrow, mast 
cells, skin, ovary, testis, nose, and blood cells (62, 63).  Endogenous cytochrome P450 
reactions include vitamin metabolism, fatty acid metabolism, sterol metabolism and 
synthesis, and eicosanoid metabolism (62).  About 26% of cytochrome P450s are involved 
in the metabolism of xenobiotics.  These specific P450s have been studied as factors 
regulating drug bioavailability and pharmacokinetics, determinants of deleterious 
drug/drug interactions, and causes of toxicity associated with different xenobiotics in 
humans (62).    
 
Cytochrome P450 Catalytic Cycle 
The P450 catalytic cycle has been well studied and is reviewed in detail (Figure 
1.1) (64).  In brief, the P450 catalytic cycle begins in the “resting state” in which a water 
molecule is bound to the ferric iron in the P450 heme cofactor.  A substrate displaces the 
water from the heme, leaving a pentacoordinated-ferric heme. This induces the iron to 
adopt a high-spin state with an increased reductive potential which allows the ferric 
complex to become a better electron acceptor from a nicotinamide adenine dinucleotide 
phosphate (NADPH) cofactor via cytochrome P450 reductase.  Oxygen then binds to the 
reduced ferrous iron, producing a ferrous dioxygen complex.  A second reduction of the 











in the catalytic cycle of P450 enzymes.  The ferric peroxo complex is a good Lewis base 
and is rapidly protonated to form a ferric-hydroperoxide species, also called compound 0.  
Compound 0 extracts an additional proton to form compound I and water.  Compound I 
then oxidizes the substrate via the activated oxygen atom (65). This catalytic step is 
followed by product release, in which oxygen is incorporated, and the heme returns to the 
resting state. 
 
Cytochrome P450-Mediated Reactions 
 Numerous endogenous and exogenous compounds that can produce physiological 
effects are hydrophobic enough to facilitate their diffusion through biological barriers and 
to reach their molecular targets.  In order to avoid accumulation of such substances and to 
avoid toxicities associated with the accumulation of such chemicals, organisms have 
evolved the P450 enzymes, which metabolize a myriad of chemicals to more hydrophilic 
products that can be more easily excreted or further metabolized to conjugates that are 
actively excreted.  Phase I enzymes, such as esterases, P450 enzymes, and monoamine 
oxidases introduce (e.g., hydroxylation) or expose (e.g., heteroatom dealkylation) more 
polar functional groups to increase water solubility and to facilitate phase 2 conjugation 
reactions and ultimately clearance.  P450 enzymes are able to catalyze numerous different 
chemical reaction mechanisms to achieve this goal, including hydroxylation and 
dehydrogenation, which are central to the work presented in this dissertation.   
Hydroxylation is the best studied and well understood P450 catalyzed reaction 
mechanism that is commonly accepted to occur via hydrogen radical abstraction followed 
by a hydroxyl radical rebound mechanism to produce an alcohol (48); this hydroxylation 
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reaction has been confirmed using other glucocorticoid substrates, but not with 
beclomethasone dipropionate (66-68).   
Dehydrogenation reactions are less studied P450-catalyzed chemical reactions that 
produce a desaturated product (69); this reaction mechanism has been shown to occur 
during the metabolism of the glucocorticoids triamcinolone, flunisolide, and budesonide 
(70-72), but not beclomethasone dipropionate.  
 
Cytochrome P450 3A (CYP3A) Family Enzymes 
The 58 human P450s are named and arranged into families based on their 
sequence homology (73-75).  One of the most important classes of P450 enzymes 
involved in drug metabolism, particularly glucocorticoid metabolism, is the CYP3A 
family of enzymes (76).  The CYP3A family is located on chromosome 7 (77) and is the 
most abundant of the P450s in many tissues, primarily the liver, intestine, and lung and 
are differentially expressed based on which transcription factors are present (78-80).   The 
CYP3A enzyme isoforms most pertinent to this dissertation include CYP3A4, CYP3A5, 
and CYP3A7.  CYP3A4 is the predominant CYP3A isoform found in the liver and 
intestine (61, 66, 81), whereas CYP3A5 predominates in the lung (61, 82, 83).  CYP3A4 
and CYP3A5 together account for over 50% of the metabolism of therapeutic molecules 
on the market today (84).   CYP3A7 is the hepatic fetal isoform (85, 86) and  Lacroix et 
al. discovered that fetal CYP3A7 predominates at birth, but is replaced by the adult 
CYP3A4 or 3A5 isoforms shortly after birth (85),  This phenomenon may be important to 




CYP3A Expression in the Lung 
Analysis of CYP3A mRNA expression in adult lung tissue found that there are 
anatomical and age related differences in the level of expression of CYP3A enzymes (61).  
Leclerc et al. found that CYP3A5 and CYP3A7 message were detected in the pulmonary 
parenchyma, but CYP3A4 message was not detected.  It was also noted that only a very 
low amount of CYP3A5 message could be detected in the bronchial mucosa (bronchial 
epithelial cells), while no CYP3A7 or CYP3A4 message was found.  Therefore, in the 
context of asthma, CYP3A5 may be the most important CYP3A enzyme because it is 
expressed in the target tissue and it is capable of altering therapeutic concentrations of 
glucocorticoids through metabolic clearance, pharmacophore modification, and 
inactivation.  There also is a difference in how CYP3A enzymes are expressed in whole 
lung tissue during development.  Preliminary work by our laboratory has shown that 
CYP3A enzyme expression profiles are different between neonates, pediatric and adult 
patients.  Neonatal tracheal washes revealed that CYP3A7 was expressed at very high 
levels, with CYP3A5 being expressed at moderate levels.  Other research has shown that 
these higher CYP3A7 levels decline in the first year of life (86) with CYP3A5 remaining 
at moderate levels and even increasing to higher levels in some patients.  Adult lung 
continues to show high levels of CYP3A5, but very low to nondetectable levels of 
CYP3A7 (unpublished data).  Although these preliminary data show differences in the 
relative expression of CYP3A enzymes, little is still known about changes in the 
developmental expression and transcription of pulmonary CYP3A enzymes.  It is possible 




Cytochrome P450 3A Enzyme Regulation 
Transcriptional regulation of hepatic CYP3A genes has been extensively studied in 
liver cell and tissues, and it is commonly accepted that many xenobiotics, including 
glucocorticoids, induce changes in expression of drug-clearing enzymes via activation of 
the nuclear pregnane X receptor (PXR) (87-91).  However,  PXR-mediated changes of 
gene expression have not been detected in human lung (92). Although there is increasing 
evidence that drug treatment will alter pulmonary CYP3A expression, including a study 
by Hukkanen et al. that showed a 4-fold increase in CYP3A5 in response to BDP 
treatment in A549 lung carcinoma cells (83), the mechanism responsible for this 
physiological response has not been well studied and remains  poorly understood.  
Likewise, the significance of this induction phenomenon with respect to glucocorticoid 
pharmacotherapy is also unknown. 
Recent reviews have shown that the glucocorticoid receptor (GR) and the 
constitutive androstane receptor (CAR) also play important roles in regulation of gene 
expression in the liver (93, 94).  Hepatocytes treated with submicromolar concentrations 
of dexamethasone have been shown to increase the expression of CAR via GR (95, 96).  
Furthermore, the induction and activation of CAR has also been  shown to increase the 
expression of  P450 enzymes, including CYP3A enzymes (94).  Therefore, it is possible 
that the regulation of the CYP3A enzymes in the lung is mediated through GR and CAR 
upon treatment.  Studies presented in this dissertation investigate the possibility that 
glucocorticoid insensitivity observed in 30% of asthmatics may be due to glucocorticoid 
induced CYP3A expression, causing increased rates of glucocorticoid clearance, and thus 
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reduced drug concentrations in the target tissue.  Specifically, the roles of GR and CAR in 
pulmonary CYP3A expression are evaluated. 
 
CYP3A4 and CYP3A5 Polymorphisms 
Because almost 50%-90% of inhaled glucocorticoids are swallowed when inhaled 
(97), CYP3A4 will play a role in the metabolism of glucocorticoids in the liver.  To date, 
there have been 22 polymorphisms of CYP3A4 described (98).  Though most of the 
polymorphisms have no effect on steroid metabolism and are not robustly expressed in 
populations (98), one that could have an impact on steroid metabolism is CYP3A4*22, 
which codes for a null enzyme (99-101).  Patients who do express this polymorphism 
could demonstrate decreased metabolism of glucocorticoids.   
Many glucocorticoids are inhaled and exhibit their efficacy in the lung.  Therefore, 
CYP3A5 polymorphisms that change glucocorticoid metabolism in lung cells would alter 
glucocorticoid efficacy.  Many polymorphisms of CYP3A5 have been reported and two 
variants, CYP3A5*3 and CYP3A5*1, are of key interest to the work presented in this 
dissertation. The most common polymorphism is CYP3A5*3, which codes for an inactive 
form of CYP3A5 in the liver due to a defective splice site (81, 102), and presumably in 
the lung.  The majority of Caucasians are homozygotes for the CYP3A5*3 allele and 
therefore do not express active CYP3A5 in the lung or elsewhere in the body.   CYP3A5*1 
codes for an active enzyme (102).  Patients expressing the CYP3A5*1 polymorphism 
would presumably have increased metabolism of glucocorticoids in the lung and therefore 
would be predicted to exhibit decreased glucocorticoid efficacy compared to individuals 
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with the CYP3A5*3 genotype.  Both genotypes were assessed throughout the studies 
reported herein. 
 
Metabolism of Beclomethasone Dipropionate 
  BDP is administered as an inhaled prodrug and becomes pharmacologically active 
in the lung by hydrolysis of an ester at the C-21 position, forming beclomethasone 17-
monopropionate [M1] (Figure 1.2) (103).  Two other metabolites previously documented 
in the literature are beclomethasone 21-monopropionate [M2], which requires the 
hydrolysis of an ester at the C-17 position, and beclomethasone [M3], which requires the 
hydrolysis of both esters (104-108).  Cell culture experiments in A549 cells attributed 
product formation to esterases (109).  However, these experiments did not contain P450 
inhibitors, and thus, the possibility that P450 enzymes also contributed to the bioactivation 
of beclomethasone dipropionate was not determined.  Preliminary research by our 
laboratory, as well as by others, has shown that P450 enzymes may be able to catalyze the 
de-esterification of BDP and thus potentially could contribute to the biological efficacy of 
this drug.  At the time this research project began, it was not known whether CYP3A 
enzymes were capable of producing the pharmacologically active BDP metabolite [M1] or 
any other metabolites (e.g., [M4] and [M5]), that were predicted from the studies of the 
metabolism of other structurally similar glucocorticoids (66-68, 70, 71).  Therefore, the 
relative rates of metabolism by CYP3A isoforms and the metabolites they produced were 







 The hypothesis for this work is that CYP3A enzymes produce the active 
metabolite as well as major clearance metabolites leading to glucocorticoid insensitivity, 
and beclomethasone dipropionate binds to GR, induces CAR, which induces the 
expression of CYP3A enzymes.  The metabolism of glucocorticoids by the CYP3A 
isoforms and the regulation of CYP3A enzymes in the lung in response to glucocorticoid 
treatment were the main objectives for this dissertation. 
 
Major Findings by Chapter 
Chapter 2 
 The ability of CYP3A isoforms to metabolize four major glucocorticoids, 
triamcinolone acetonide, flunisolide, budesonide, and fluticasone propionate, had not been 
previously documented and was evaluated.  CYP3A5 was able to metabolize all four 
glucocorticoids.  CYP3A4 metabolized triamcinolone acetonide, budesonide, and flutica-
sone. CYP3A7 metabolized budesonide, fluticasone propionate, and triamcinolone 
acetonide, but at lower rates than CYP3A4 and CYP3A5.  The major metabolites 
produced for triamcinolone acetonide, flunisolide, and budesonide were 6β-hydroxylation 
and Δ6-dehydrogenation.  Hydrolysis of an ester on the D-ring of the glucocorticoid by 
CYP3A enzymes occurred for fluticasone propionate and triamcinolone acetonide.  Novel 
metabolites, 21-nortriamcinolone acetonide and Δ6-flunisolide, were isolated and 
identified using NMR.   This work had been published in the journal Drug Metabolism 





The ability of CYP3A isoforms to metabolize BDP was first evaluated.  The 
results indicated that only CYP3A4 and CYP3A5 are able to metabolize BDP, exhibiting 
similar rates, while CYP3A7 does not metabolize BDP.  Studies with in vitro incubations, 
including recombinant P450 enzyme, demonstrated that CYP3A4 and CYP3A5 produce 
clearance compounds, [M4] and [M5], and that the combined action of esterases and 
CYP3A4 produced [M6], a de-esterified, hydroxylated product.  Further investigation 
using cell culture experiments, showed only the formation of [M5] by A549 cells (lung 
adenocarcinoma cells).  However, both [M4] and [M5] were detected in liver cell culture 
(DPX2 cells).  [M6] was not detected in cell culture experiments.  This work has been 
published in the Journal of Pharmacology and Experimental Therapeutics (110).  
 
Chapter 4  
Studies focused on the regulation of CYP3A enzymes in response to 
glucocorticoid treatment in various lung cell culture models.  In A549 cells there was a 2-
fold induction of CYP3A5 mRNA upon BDP treatment, but neither CYP3A4 nor 
CYP3A7 mRNA were detected, even with BDP (and other glucocorticoid treatment).  The 
induction of CYP3A5 was blocked by inhibiting the formation of the active metabolite 
[M1] through inhibition of esterase activity.  Furthermore, inhibition of all P450 and 
esterase activity (through 1-ABT and esterase inhibitors) and treatment with [M1] was 
sufficient to induce CYP3A5 mRNA.  Blocking the glucocorticoid receptor using a 
competitive antagonist, ketoconazole, or knocking down GR expression using siRNA, 
blocked the induction of CYP3A5, suggesting this induction occurred through the 
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glucocorticoid receptor.  The constitutive androstane receptor did not participate in the 
induction of CYP3A5.   Additional investigations of this regulatory pathway in primary 
cell cultures, such as NHBE, SAEC, and lobar cells, showed that it could not be replicated 
with these model systems.  This suggests that there is a deficit in current lung models used 
to study not only the regulation of CYP3A5 in the lung in response to glucocorticoid 
treatment, but also the metabolism of glucocorticoids by CYP3A enzymes in the lung.  
This work was not published prior to submission of the final version of this dissertation. 
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REGULATION OF CYP3A GENES BY GLUCOCORTICOIDS 
 






 Inhaled glucocorticoids are the first line treatment for patients with persistent 
asthma.  However, approximately 30% of patients do not respond to treatment due to 
glucocorticoid insensitivity, which may involve excess metabolic clearance of the 
glucocorticoids by CYP3A enzymes in the lung.  CYP3A4, 3A5, and 3A7 enzymes 
metabolize glucocorticoids and glucocorticoids induce CYP3A5 in A549 cells.  However, 
the mechanism by which CYP3A5 expression is regulated in A549 cells in response to 
glucocorticoids has not determined.  In hepatocytes glucocorticoids bind to the 
glucocorticoid receptor, which induces the expression of the constitutive androstane 
receptor, which binds the retinoid X receptor α, leading to the induction of CYP3A4, 3A5, 
and 3A7.  This pathway was evaluated as the mechanism for CYP3A5 mRNA induction 
by glucocorticoids in A549, BEAS-2B, NHBE, SAEC, lobar, and tracheal epithelial cells.  
In A549 cells, beclomethasone 17-monopropionate ([M1]) induced CYP3A5 mRNA 
through the glucocorticoid receptor.  CYP3A5 mRNA induction by five different 
glucocorticoids was attenuated by inhibiting the glucocorticoid receptor using 
ketoconazole, and for beclomethasone dipropionate, using siRNA –mediated inhibition of 
53 
 
glucocorticoid receptor expression.  The constitutive androstane receptor was not 
expressed in lung cells.  SAEC cells, a primary lung cell line, expressed CYP3A5, but 
CYP3A5 mRNA was not induced by glucocorticoid treatment despite evaluating a 
multitude of cell culture conditions.  None of the other lung cells expressed CYP3A4, 3A5 
or 3A7 mRNA.  These studies demonstrate that CYP3A5 message is induced in response 
to glucocorticoid treatment in A549 cells via the glucocorticoid receptor, but an additional 
undefined regulatory process may exist in primary lung cells.   
 
Introduction 
 Inhaled glucocorticoids are the first line treatment for asthma (1-3).  
Glucocorticoids bind to the glucocorticoid receptor to reduce the expression of genes that 
produce a variety of pro-inflammatory mediators and mucus in the lung (4-6).  The most 
commonly prescribed glucocorticoids are beclomethasone dipropionate (BDP), 
triamcinolone acetonide (TCL), budesonide (BUD), fluticasone propionate (FLT), and 
flunisolide (FLN) (1).  BDP is a prodrug and requires removal of the C-21 propionate 
group to become pharmacologically active; the active drug is beclomethasone 17-
monopropionate, referred to as [M1] (Scheme 4.1) (7).  Pharmacological inactivation and 
clearance of glucocorticoids, such as BDP and its active metabolite [M1], is mediated, in 
part, by cytochrome P450 (CYP) enzymes (Scheme 4.1), mainly the CYP3A enzymes., 
CYP3A4, 3A5, and 3A7. 
In humans, CYP3A4, 3A5, and 3A7 are involved in glucocorticoid metabolism (8-
11).  CYP3A4 is the most abundant CYP3A enzyme in the liver and intestines (8, 12, 13), 








fetal liver, but diminishes after birth when CYP3A4 becomes the dominant adult hepatic 
CYP3A enzyme (17, 18).  Expression of CYP3A7 in fetal and adult respiratory tissue has 
also been reported (16).  
 Regulation of CYP3A enzymes in response to glucocorticoid treatment has been 
extensively characterized in the liver, but little is known about this phenomenon in the 
lung.  In hepatocytes, CYP3A enzyme induction is mediated by the pregnane X receptor 
(PXR) (19, 20).  However, PXR is not expressed in the lung (21).  The glucocorticoid 
receptor (GR) and the constitutive androstane receptor (CAR) also regulate CYP3A 
induction by glucocorticoids in the liver (22, 23).  Briefly, glucocorticoids bind GR in the 
cytosol, which forms a homodimer and translocates to the nucleus, leading to increased 
transcription of CAR.  CAR forms a heterodimer with the retinoid X receptor alpha 
(RXRα), which binds to the CAR/RXR- response element and induces the expression of 
CYP3A enzymes (Figure 4.1).  This pathway, however, has not been demonstrated in the 
lung. 
 The purpose of this study was three fold: 1) to evaluate changes in the expression 
of CYP3A mRNA in lung cells treated with glucocorticoids; 2) to determine if the 
GR/CAR/RXRα pathway was responsible for glucocorticoid-induced changes in CYP3A 
mRNA expression; and 3) to determine the role of metabolism in this phenomenon.  The 
cell lines used in this study were BEAS-2B (immortalized bronchial epithelial cell line), 
NHBE (normal human bronchial/tracheal epithelial cells), lobar epithelial cells (secondary 
bronchus epithelial cells), primary cells recovered from tracheal washes of pediatric 
patients on mechanical ventilators, SAEC (small airway epithelial cells), and A549 









cells by BDP (11) and other glucocorticoids would occur via a mechanism involving 
GR/CAR/RXRα, as previously documented in hepatocytes. 
 
Materials and Methods 
Chemicals, Reagents, and Treatments 
Beclomethasone dipropionate (BDP), triamcinolone acetonide (TCL), fluticasone 
propionate (FLT), flunisolide (FLN), budesonide (BUD), prednisolone, ammonium 
acetate, eserine, and methanol were purchased from Sigma-Aldrich Chemical Company 
(St. Louis, MO).  Paraoxon was purchased from Chem Service (West Chester, PA).   
 
Cell Culture 
A549 cells (American Type Culture Collection, Manassas, VA) were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) plus 5% fetal bovine serum (Life 
Technologies, Grand Island, NY).  SAEC cells (LONZA, Walkersville, MD; patient 
numbers 11662, 14453, 14457) were cultured in small airway epithelial growth medium, 
supplemented with the SAGM bullet kit.  Cells were cultured with and without 
hydrocortisone by adding or not adding the hydrocortisone component from the SAGM 
bullet kit.  NHBE cells (LONZA; patient numbers 15268, 5S03795) were grown in 
bronchial epithelial cell growth medium (BEGM Bullet kit) (LONZA).  BEAS-2B cells 
(American Type Culture Collection) were cultured in LHC-9 medium (Life 
Technologies).  Lobar cells (patient number 01334) were cultured in BronchiaLife Basal 
Medium supplemented with the BronchiaLife B/T supplement kit (Lifeline Cell 




pre-coated with LHC basal medium (Life Technologies).  Tracheal epithelial cells were 
recovered from tracheal washes from mechanically ventilated pediatric patients in the 
neonatal intensive care unit and pediatric intensive care unit at Primary Children’s 
Medical Center at the University of Utah, with IRB approval (00026839).  Briefly, cells 
were separated from sputum by centrifugation at 900 xg for 30 min in 14 mL of 
DMEM/F12 media.  Cells were plated in a 12-well plate pre-coated with 2% gelatin (Life 
Technologies) and cultured in DMEM/F12 media + 10% fetal bovine serum (FBS) (Life 
Technologies). All cells were cultured in an atmosphere of 5% CO2:95% air at 37ºC.  
 
Cell Treatments 
Cell treatments were prepared in treatment media with a final concentration of 
DMSO less than 1%.  Cells were treated at ~70% confluence (11).  A549 cells were 
treated in OPTIMEM (Life Technologies) and SAEC cells were treated in growth media 
with and without hydrocortisone and with and without heat inactivated and/or charcoal-
stripped FBS.  All other cell lines were treated in their respective growth medium, also 
heat inactivated to eliminate esterase activity from the FBS which would metabolize BDP 
before it could diffuse into the cells.  Cytotoxicity assays were performed using the 
Dojindo Cell counting kit-8 (Dojindo Laboratories, Rockville, MD) to determine 
glucocorticoid, esterase inhibitor, and ketoconazole concentrations exhibiting <20% 
cytotoxicity in A549 cells.  All other cell lines were treated with the same concentrations 
as determined with A549 cells.  Glucocorticoid treatments were as follows: BDP (10 μM), 
TCL (1 μM), BUD (10 μM), FLT (1 μM), and FLN (100 nM).  Pre-treatments in various 




inhibitors (1:1 mixture of eserine and paraoxon, each at 175 μM, to inhibit [M1] 
formation), and 1-aminobenzotriazole (1-ABT; 200 μM, to inhibit P450-mediated 
metabolism) for 2 h prior to a 22 h glucocorticoid cotreatment.  Controls were treated with 
an equivalent concentration of DMSO.  All A549 cell treatments were carried out in 6-
well plates for 24 h (n=6).  All other cell lines were cultured in precoated 12-well plates 
and treated for 24 h (n=3).     
 
Analysis of BDP Metabolites 
After treatment, BDP and BDP metabolites were extracted from the collected 
media by adding 2x volume (6 mL for A549, 4 mL for all other cell lines) methyl tert-
butyl ether containing 1 nM prednisolone (internal standard for quantification) and 
shaking for 25 min.  Samples were clarified by centrifugation, the organic fraction was 
collected, dried under air, reconstituted in 100 µL 1:1 H2O:MeOH, clarified again by 
centrifugation, and transferred to autosampler vials for analysis by liquid chromatography-
mass spectrometry (LC/MS/MS).  LC/MS/MS was conducted on a Thermo LCQ 
Advantage Max ion trap instrument equipped with a Finnigan Surveyor LC pump, 
Surveyor Autosampler and universal Ion Max source operated with Thermo Xcalibur 
software version 2.0 (Thermo Fisher Scientific, Waltham, MA) as previously described 
(11).  
 
Quantitative Reverse Transcription-PCR 
Total RNA was isolated from cells using TRIzol reagent (Life Technologies).  




RAD, Hercules, CA).  qPCR was performed using either LightCycler 480 Probes Master 
mix (CYP3A5) or LightCycler 480 SYBR Green I Master Mix (all other genes) (Roche, 
Indianapolis, IN) with a Light-Cycler 480 System.  The PCR program for probe mix 
consisted of a 5 min incubation at 95ºC, followed by 45 cycles of 95ºC for 10s, 55ºC for 
30s, then 72ºC for 1s.  The PCR program for SYBR Green I mix consisted of a 5 min 
incubation at 95ºC, followed by 40 cycles of 95ºC for 10s, 63ºC for 5s for CYP3A4, 
CYP3A7 and β2-microglobulin.  For GR and CAR, annealing was performed at 65ºC for 
5s and extension at 72ºC for 10s.  mRNA copy number was determined from standard 
curves for each gene and was normalized using β2-microglobulin.  Primer sequences for 
the various genes are listed in Table 4.1 (24).   
 
siRNA-Mediated Protein Knockdown 
Pre-annealed, short interfering “Smart Pool” siRNAs specific to human GR were 
purchased from Dharmacon (Waltham, MA).  siRNA directed against GFP (25) was used 
as a negative control with the following sequences: 5′-CUGGAGUUGUCCCAAUUCCT 
T-3′ and 5′-AGAAUUGGGACAACUCCAGTT-3′ (the 2-nucleotide overhanging of 2′-
deoxythymidine is indicated as TT and denoted by underlines).  Control siRNA was 
synthesized at the University of Utah oligonucleotide synthesis core and annealed by 
combining 40 µM of each strand and incubating in annealing buffer (100 mM potassium 
acetate, 30 mM HEPES KOH, 2 mM magnesium acetate adjusted to pH 7.4) for 1 min at 
90ºC followed by 1 h at 37ºC, in a final volume of 0.5 mL.  A549 cells were plated into 6-
well plates containing 20 nM siRNA per well, previously complexed with Lipofectamine 














The cells were grown for 48, 72, and 96 h to determine the time at which maximum 
decreases in GR mRNA occurred (72 h).  In subsequent experiments, cells were treated 
with DMSO, 10 µM BDP, or 10 μM BDP + 175 µM esterase inhibitors (1:1 
eserine:paraoxon) for 24 h to determine the effects of attenuated GR expression on the 
induction of CYP3A5 in A549 cells. 
 
Results 
Inhibition of [M1] Formation Prevented CYP3A5 mRNA Induction by  
BDP in A549 Cells 
 Media from A549 cells treated with BDP (10 µM) for 24 h was extracted and 
analyzed for metabolites of BDP produced by CYP3A enzymes.  The only CYP3A-
mediated metabolite detected was [M5] (Scheme 4.1 and Figure 4.2A) (11).  For the 
remainder of the studies, [M1], the active metabolite, was used as a marker for esterase 
activity and [M5] was used as a marker for CYP3A5 activity.  BDP treatment significantly 
induced the expression of CYP3A5 mRNA (~2-fold) compared to the DMSO control 
(Figure 4.2B).  CYP3A4 and CYP3A7 mRNA was not detected in A549 cells, as 
previously documented (11, 16).   Inhibiting the production of [M1] using esterase 
inhibitors also blocked the induction of CYP3A5 mRNA (Figures 4.2A and 4.2B); 
esterase inhibitor (EI) treatment alone had no effect on CYP3A5 expression.  1-ABT, a 
mechanism-based inactivator of P450 enzymes, also inhibited esterase activity (i.e., [M1] 












[M1] was Sufficient to Induce CYP3A5 mRNA in A549 Cells 
Cells were treated with [M1] in the absence and presence of 1-ABT and esterase 
inhibitors.  [M1] treatment was sufficient to induce CYP3A5 mRNA (~2-fold), 
independent of esterases (Figure 4.2B), indicating that CYP3A5 mRNA induction in 
A549 cells was mediated by [M1], presumably involving GR. 
 
GR, but not CAR, Regulated the Induction of CYP3A5 mRNA in  
A549 Cells  
GR and CAR mRNA were quantified in A549 cells.  A significant increase in GR 
message (~2.4-fold) was observed following 24 h treatment with BDP (Table 4.2).  CAR 
mRNA was not detected in A549 cells prior to or following glucocorticoid treatment 
(Table 4.2), consistent with previous studies (15), suggesting that GR, not CAR, was 
responsible for the induction of CYP3A5 message in A549 cells. 
 
Inhibition of GR with Ketoconazole Attenuated CYP3A5  
mRNA Induction by Glucocorticoids in A549 Cells    
Ketoconazole is a competitive antagonist of GR (24).  Ketoconazole alone had no 
significant effect on CYP3A5 mRNA expression (Figure 4.3A).  As the concentration of 
ketoconazole was decreased, dose-dependent increases in the expression of CYP3A5 
mRNA were observed for BDP, TCL, FLT, BUD, and FLN (Figure 4.3A-E): BDP caused 
a ~2-fold induction, BUD caused a ~4-fold induction, TCL caused a ~5.5-fold induction, 
FLT caused a ~3.5-fold induction, and FLN caused a ~5.5-fold induction, relative to their 














mRNA in A549 cells was mediated by GR.  
 
siRNA-mediated Knockdown of GR also Attenuated CYP3A5 mRNA Induction 
 by BDP in A549 Cells 
Cells were transfected with siRNA and grown for 48, 72, and 96 h to determine the 
time of maximum GR mRNA suppression (Figure 4.4A).  Maximum suppression 
occurred as early as 48 h, but the 72 h time point was chosen for further experiments to 
ensure efficient GR protein depletion.  An approximate 2-fold induction of CYP3A5 
mRNA was observed in A549 cells following treatment with BDP in control cells 
transfected with “nonsense” siRNA directed against GFP.  Consistent with previous 
results (Figures 4.2A and 4.2B), CYP3A5 mRNA induction was prevented by esterase 
inhibitors (Figure 4.4B).  Cells transfected with siRNA targeted for GR mRNA showed no 
change in CYP3A5 mRNA with BDP treatment, further confirming the role of GR in 
directly regulating the induction of CYP3A5 mRNA in A549 cells treated with BDP and 
presumably the other glucocorticoids used in Figure 4.3. 
 
CYP3A5 was not Expressed or Induced by Glucocorticoid  
Treatment in Tracheal/Bronchial Epithelial Cells 
Neither CYP3A5 mRNA expression nor induction of CYP3A5 mRNA following 
BDP or other glucocorticoid treatment was observed in NHBE, BEAS-2B, lobar, and 










SAEC Cells Expressed CYP3A5, but mRNA for CYP3A5 was  
not Induced by Glucocorticoid Treatment 
SAEC cells from three separate patients were evaluated for CYP3A5 mRNA 
expression and induction in response to glucocorticoid treatment.  Initial experiments 
demonstrated that mRNA for CYP3A, but not CYP3A4 or 3A7, was expressed in one of 
the three SAEC samples (patient #11662), but that expression levels were not altered by 
glucocorticoid treatment.  It was hypothesized that the high concentration of 
hydrocortisone (500 µM) in the SAEC growth media prevented the induction of CYP3A5 
mRNA by substantially lower concentrations of the glucocorticoids used in the treatments.  
Elimination of hydrocortisone from the media decreased the basal expression of CYP3A5 
mRNA (Figure 4.5).  However, no change in mRNA abundance was observed over a 24 h 
treatment period with BDP.  Furthermore, neither increasing the treatment concentration 
of BDP to 50 µM, nor treatment with [M1] at 150 µM led to an increase in CYP3A5 
mRNA in SAEC cells.  It was subsequently hypothesized that phthalates or other 
substances in the FBS might alter GR function and CYP3A5 mRNA induction by 
glucocorticoids (26).  However, neither heat inactivation nor charcoal-stripping of the 
FBS in media with and without hydrocortisone led to CYP3A5 mRNA induction.  The 
various manipulations to SAEC culture conditions and results for CYP3A5 induction are 
summarized in Table 4.3. 
 
Discussion 
Inhaled glucocorticoids are used to control undesirable symptoms in asthmatic 
















treatment (6).  Prior work demonstrated that the five most commonly prescribed 
glucocorticoids used in the treatment of asthma are metabolized by CYP3A enzymes, 
specifically CYP3A4, CYP3A5, and CYP3A7 (10, 11).  Therefore, it has been proposed 
that unusually high rates of metabolism of glucocorticoids in lung cells by these enzymes 
might contribute to the decrease and/or lack of efficacy in some individuals.  However, it 
is not understood how the expression of CYP3A enzymes is regulated in the lung in 
response to glucocorticoid treatment, despite extensive knowledge of this phenomenon in 
hepatocytes and the liver (22).  
Using A549 cells, it was demonstrated that CYP3A5 mRNA was induced by 
glucocorticoid treatment (Figure 4.2B and 4.3A-E); neither CYP3A4 nor CYP3A7 mRNA 
were detected in A549 cells.  Subsequent studies using a competitive antagonist of GR 
(ketoconazole) and siRNA selective for GR mRNA, demonstrated that inhibition of GR 
function prevented the induction of CYP3A5 mRNA by BDP and other glucocorticoids in 
A549 cells (Figure 4.3A-E and 4.4B).  It was also demonstrated that CAR mRNA was not 
expressed by lung cells, consistent with previous RT-PCR data (15), and therefore could 
not be involved in the regulation of CYP3A5 expression by glucocorticoids as occurs in 
hepatocytes.  It was concluded that CYP3A5 expression was directly regulated by GR.  
Schuetz et al. (27) previously described two “half sites” of GR (TGTTCT) separated by 
160 bp in the promoter region of CYP3A5 in HepG2 cells and in human and rat 
hepatocytes.  It was demonstrated that dexamethasone induced the expression of CYP3A5 
by the GR homodimer binding to these two joined “half-sites” which could be blocked by 
RU-486, a GR antagonist.  It is plausible these same sites are involved in the regulation of 




Regardless of the exact mechanism of regulation, the current results illustrate that 
glucocorticoids have the capacity to induce the expression of CYP3A5 in A549 cells.  
These data, in conjunction with prior metabolism studies of glucocorticoids by this 
laboratory, support the hypothesis that treating patients with glucocorticoids could 
increase levels of CYP3A5 in the lung, and therefore increase pulmonary glucocorticoid 
metabolism, ultimately increasing clearance, and potentially decreasing the concentration 
of active drug in lung cells.  Though most of the population expresses the inactive form of 
CYP3A5 (CYP3A5*3) (13, 28) those expressing CYP3A5*1, the active form of CYP3A5 
(13), could exhibit increased clearance of the drug, and therefore could account for at least 
some of the 30% of patients who do not respond to inhaled glucocorticoid therapy. 
In order to further support the hypothetical scenario above, the induction of 
CYP3A enzymes by glucocorticoids in various lung cells was studied.  CYP3A5 mRNA 
expression was quantified in primary lung cells, which presumably more closely model 
epithelial cells of the human respiratory tract and lung.  NHBE, lobar, and cells recovered 
from tracheal washes of mechanically ventilated children were evaluated for CYP3A 
enzyme expression and induction by glucocorticoids.  Results in Table 4.2 show that 
CYP3A mRNA was not expressed in cells of the conducting airways in response to 
glucocorticoid treatment, indicating that these epithelial cells likely do not play a role in 
CYP3A-dependent metabolism of glucocorticoids in the lung.  In contrast, SAEC cells, 
representing cells of the distal bronchioles, alveolar ducts, and alveoli, did express 
CYP3A5 (Table 4.2).  However, there was no change in CYP3A5 message when these 
cells were treated with glucocorticoids.  A thorough examination of potential confounding 




µM) in the growth media.  Because cells were treated with only 10 µM BDP, it would 
stand to reason that no change in CYP3A5 mRNA would occur because CYP3A5 
expression would already be maximized as a result of hydrocortisone activating the GR 
pathway.  Experiments conducted in A549 cells showed that culturing cells in 500 µM 
hydrocortisone increased the basal expression of CYP3A5 mRNA by 2-fold, masking the 
induction routinely observed using 10 µM BDP for 24 h.  When A549 cells were 
subsequently cultured in media without hydrocortisone for a 48 h, providing sufficient 
time for a “wash out” of the hydrocortisone, the basal expression of CYP3A5 mRNA was 
reduced, and ~2-fold induction of CYP3A5 mRNA occurred with the 10 µM BDP, 24 h 
treatment.  Therefore, hydrocortisone was omitted from the SAEC growth media.  
Subsequent experiments in SAEC cells showed no change in CYP3A5 mRNA in response 
to glucocorticoid treatment (Figure 4.5), albeit removal of hydrocortisone from the media 
caused a slight decrease in the basal level of CYP3A5 mRNA expression, suggesting GR 
plays a role in the regulation of CYP3A5.  It is feasible that because cells had been 
exposed to such high concentrations of hydrocortisone during their isolation and 
expansion, that 10 µM of BDP was not sufficient to induce CYP3A5 mRNA, even after 
culturing the cells in the absence of hydrocortisone for multiple division cycles.  
Therefore, the concentration of BDP was increased to 50 µM and an additional treatment 
group using 150 µM [M1] was added.  Again no increases in CYP3A5 mRNA were 
observed.  Heat-inactivated and charcoal-stripped FBS were also utilized to remove 
potential interfering compounds from FBS, and still no change was observed.  To our 
knowledge, no one has observed a change in CYP3A mRNA expression in any primary 




induction have been documented in mouse lung following dexamethasone treatment (29).  
As such, additional studies using animal models and relevant samples from human 
patients need to be evaluated in order to conclusively confirm or reject the hypothesis that 
CYP3A genes are regulated in response to glucocorticoid treatment in human lungs, since 
current in vitro models are unexplainably limited in value for such studies. 
In summary, the data presented herein demonstrate that, in A549 cells, 
glucocorticoid binding to the glucocorticoid receptor regulates the expression of CYP3A5, 
and therefore, corroborates the hypothesis that increased metabolism of glucocorticoids 
may occur in some patients.   However, further research is needed to determine if changes 
in CYP3A5 expression occur in the human respiratory tract similar to A549 cells, the 
precise mechanism by which this process occurs, and whether changes in the local 
metabolism of glucocorticoids by CYP3A5 ultimately impact glucocorticoid efficiency.   
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 The studies described in this dissertation focused on two research objectives: first 
to characterize the metabolism of commonly prescribed inhaled glucocorticoids by 
CYP3A4, CYP3A5, and CYP3A7 enzymes; and second, to evaluate how CYP3A enzyme 
expression may be altered in lung cells by glucocorticoid treatment.  Using recombinant in 
vitro systems, CYP3A4 and CYP3A5 were shown to be the principle enzymes involved in 
the metabolic decomposition of beclomethasone dipropionate (BDP), triamcinolone 
acetonide (TCL), fluticasone propionate (FLT), and budesonide (BUD).  CYP3A7 did not 
metabolize BDP or flunisolide (FLN), but did metabolize TCL, FLT, and BUD, albeit 
typically at lower rates than those observed for CYP3A4 and 3A5.  CYP3A4 was the only 
enzyme that metabolized FLN.  All CYP3A-mediated metabolism resulted in the 
formation of metabolites that were presumed to be pharmacologically inactive (1, 2).  
Common P450 metabolites produced for FLN, TCL, BUD, and BDP were the result of 
6β-hydroxylation and Δ6-dehydrogenation.  Immortalized and primary lung cell culture 
systems were used to evaluate CYP3A metabolism of glucocorticoids as it related to the 
induction of CYP3A gene transcription through GR and the constitutive androstane 
receptor (CAR).  Studies performed using A549 cells demonstrated that only GR 
participated in the induction of CYP3A5 by glucocorticoids, a mechanism that was unique 
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from liver cells.  BEAS-2B, NHBE, and lobar cells, as well as cells collected from 
tracheal washes of pediatric patients did not express any of the CYP3A enzymes.  
Selected patient samples of SAEC cells did express CYP3A5, but induction of CYP3A5 
mRNA by glucocorticoid treatment was not observed.  Furthermore, manipulations to the 
SAEC cell culture system did not lead to the induction of CYP3A5 by glucocorticoid 
treatment, as was observed in A549 cells.  The metabolism data and the gene induction 
data from this research project provide possible explanations as to why there exists a 
broad range of glucocorticoid efficacy in patients with asthma. 
 Glucocorticoids are first-line therapeutics for treating asthma, but roughly 30% of 
patients are not responsive to treatment (3).  A possible explanation for this “steroid 
insensitivity” may be that excess metabolism of glucocorticoids to clearance metabolites 
by CYP3A enzymes could decrease the bioavailability of the pharmacologically active 
drug systemically and/or in lung cells.  The results described in this dissertation support 
this hypothesis by demonstrating that CYP3A enzymes metabolize glucocorticoids to 
metabolites that are predicted from published structure activity studies (1, 2) to be 
pharmacologically less active or inactive.  For FLN, TCL, and BUD, the major 
metabolites produced by CYP3A enzymes were hydroxylated and dehydrogenated 
products resulting from metabolism at the 6 position of the B ring.  Metabolism of FLT 
and TCL by CYP3A enzymes produced D ring metabolites arising from ester cleavage.  
For BDP, CYP3A5 produced a hydroxylated metabolite, [M4], and a dehydrogenated 
metabolite, [M5], likely occurring at the C6 position of the B ring, similar to the other 
glucocorticoids.  CYP3A4 also generated these metabolites at similar rates as CYP3A5, 
but in addition produced [M6], a hydroxylated and de-esterified metabolite, arising from 
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the combined action of esterases and CYP3A4.  Because CYP3A5 metabolism leads to 
the pharmacological inactivation of four glucocorticoids, it stands to reason that increased 
expression of CYP3A5 enzyme in the lung could also decrease glucocorticoid efficacy.  
The CYP3A5 enzyme has two major polymorphisms: CYP3A5*1 and CYP3A5*3.  The 
majority of the Caucasian population expresses CYP3A5*3, which codes for an inactive 
CYP3A5 enzyme (4, 5), and therefore would not metabolize glucocorticoids regardless of 
the level of enzyme expressed.  However, about 20% of the Caucasian population, and 
approximately 90% of the African American population, express CYP3A5*1, which codes 
for an active enzyme.   Such individuals are characterized as “extensive metabolizers” (6).  
This population, in particular, could exhibit increased metabolism of glucocorticoids in 
the lung, particularly if CYP3A5 is induced by the glucocorticoid treatment, potentially 
causing a decreased benefit from glucocorticoid treatment.  This intriguing hypothesis 
requires further investigation to be confirmed or refuted and should be carefully evaluated 
in future studies of factors that influence glucocorticoid efficacy.   
 In addition to exploring how CYP3A enzymes metabolized glucocorticoids, it was 
important also to determine if these enzymes were induced in the lung in response to 
glucocorticoid treatment.  Previous research has established that in the liver, treatment 
with submicromolar concentrations of glucocorticoid leads to the induction of GR.  GR 
then forms a homodimer and translocates into the nucleus where it induces transcription of 
CAR.  CAR protein then forms a heterodimer with the retinoid X receptor (RXRα) which 
increases the transcription of CYP3A genes (7).  This pathway, however, had not been 
explored in the lung.  A549 cells were used as a general lung cell model to evaluate 
whether this pathway was also responsible for CYP3A gene expression in lung cells.  
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Experiments demonstrated that treatment with BDP induced CYP3A5*1 ~2-fold after 24 
h.  Blocking the production of [M1], the active metabolite of BDP, using esterase 
inhibitors, attenuated the induction of CYP3A5.  Inhibiting both cytochrome P450 
enzymes and esterases, using 1-ABT (a mechanism-based inhibitor of CYP enzymes) and 
a esterase inhibitor cocktail (eserine and paraoxon), and treating with [M1] led to the 
induction of CYP3A5 mRNA, demonstrating that [M1] was both required and sufficient 
to induce CYP3A5 mRNA expression and that GR was involved in this pathway.  This 
conclusion was further verified using siRNA targeted against GR mRNA: maximal 
depletion of GR mRNA correlated with inhibited induction of CYP3A5 mRNA by BDP.  
CAR mRNA, however, was not detected in A549 cells, prior to or following treatment 
with glucocorticoids, suggesting that CAR did not play a role in the induction of CYP3A5 
mRNA in A549 cells, which had been assumed based on studies using liver cells.   
 Primary lung cells were also used to confirm the mechanism for CYP3A5 
induction in A549 cells.  Primary cells representative of the tracheal and bronchial 
epithelium did not express CYP3A enzymes.  These data suggest that CYP3A enzymes 
likely do not contribute to the metabolism of BDP in the conducting airways.  SAEC cells, 
which are isolated from the distal bronchioles, alveolar ducts, and alveoli, did express 
CYP3A5, but not CYP3A4 or CYP3A7. Surprisingly, CYP3A5 mRNA was not induced 
in SAEC cells by glucocorticoid treatment.  Various manipulations were made to the 
SAEC culture conditions to evaluate the GRCYP3A5 regulatory pathway characterized 
in A549 cells.  However, even with extensive manipulation of cell culture media 
supplementation, treatment concentrations, and treatment durations, CYP3A5 mRNA was 
not inducible in SAEC cells.  Further investigation of literature related to this topic 
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showed that all of the research completed to date had been performed in A549 cells and 
no work had been published using primary cell culture systems.  Because the results of the 
primary cells were inconclusive, it was not possible to determine if the pathway of 
CYP3A5 mRNA induction demonstrated in A549 cells also functioned in the human lung.  
Completing a human study to evaluate this pathway would not be possible due to ethical 
issues with extracting human lung samples out of healthy individuals.  It may be a suitable 
substitute to culture mouse bronchiolar and alveolar tissue and/or cells and perform the 
same experiments described with A549 cells to determine if glucocorticoid treatment will 
induce Cyp3a mRNA through GR in mouse lung.  This experiment could be taken a step 
further by utilizing a mouse model, BALB/c mice (a common asthma model), and 
administering two doses of glucocorticoids via tracheal installation, 12 h apart, for 24 h.  
The lungs would then be extracted, homogenized, and assayed for Cyp3a mRNA, 
specifically Cyp3a11, Cyp3a16, Cyp3a41, and Cyp3a13, which are homologous to human 
Cyp3a enzymes (8, 9).  If Cyp3a mRNA increased in mice following treatment as 
compared to control mice, it would agree with the work completed in A549 cells, and 
would further support the hypothesis that glucocorticoid treatment increases CYP3A5 
expression in human lung.  Such results would also justify additional mechanistic studies 
to determine how glucocorticoids induce CYP3A in the intact lung system, including 
studies to link the effects of metabolic capacity on glucocorticoid efficacy. 
The cumulative results presented in this dissertation unquestionably demonstrate a 
role for GR in the induction of CYP3A5 mRNA in A549 cells.  However, it remains 
unclear if there are other regulatory elements involved, which limit CYP3A5 induction in 
primary lung cells.  Studies conducted by Schuetz et al. identified two “half-sites” 
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(TGTTCT) of the glucocorticoid response element separated by 160 bp in the CYP3A5 
promoter region in HepG2 cells (immortalized hepatic cells) and primary human and 
mouse hepatocytes (10).  It was demonstrated that mutating the GR homodimer inhibited 
the induction of CYP3A5 message with dexamethasone treatment.  It was also established 
that mutating either of these DNA “half sites” of the CYP3A5 promoter region inhibited 
the binding of the GR homodimer and therefore blocked the induction of CYP3A5 with 
dexamethasone treatment.  Thus, it is plausible that a similar role for these half-sites 
occurs in A549 cells.  Future experiments in A549 cells could be conducted by mutating 
one or both of these half-sites in the CYP3A5 promoter to confirm their role in CYP3A5 
expression and induction by glucocorticoids in lungs cells.  Specifically, if these 
mutations block the induction of CYP3A5 after glucocorticoid treatment, then a direct 
interaction between GR and CYP3A5 occurs.  If the mutations do not block CYP3A5 
induction, then another regulatory element and/or elements is/are involved, and more 
thorough studies of promoter region binding elements would need to be completed and 
evaluated in the primary lung cell models, particularly of negative regulatory factors exist.     
The known mechanism of action for glucocorticoids is to bind to GR, which ultimately 
decreases inflammation and mucus production in the lung by increasing the transcription 
of annexin 1, interleukin 10, and inhibitor of nuclear factor kappa B (3, 11-14).  The 
glucocorticoid receptor can also modulate expression of proinflammatory genes by 
binding to transcription factors such as nuclear factor kappa B and activator protein-1 and 
decrease their expression (15).  These actions are considered to be direct genomic actions 
of glucocorticoids (16).  A major finding of this work was that binding of glucocorticoids 
to GR, or genomic action, induces the expression of CYP3A5 mRNA in A549 cells.  
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Presuming a similar phenomenon also occurs in the human lung, it is possible that 
continued use of inhaled glucocorticoids could promote higher levels of CYP3A5.  For 
patients that express the active form of CYP3A5, this could increase metabolism of 
glucocorticoids in lung cells, and therefore, potentially reduce the efficacy of 
glucocorticoids over time (see Figure 5.1 for a schematic representation of this concept).  
A possible way to combat this cycle would be to include a selective CYP3A inhibitor that 
could be coadministered by inhalation with the glucocorticoid.  An inhibitor that could be 
used is the antifungal drug, ketoconazole, which is a well-known inhibitor of CYP3A 
enzymes.  Experiments conducted in A549 cells with ketoconazole at 1 µM and 
glucocorticoids at 10 µM (BDP and BUD), 1 µM (TCL and FLT), and 100 nM (FLN) 
showed that CYP3A5 was sufficiently inhibited, because no CYP3A-generated 
metabolites were produced.  Additionally, ketoconazole itself did not inhibit GR at this 
concentration, because induction of CYP3A5 was not blocked, and therefore, the 
glucocorticoid would still be able to target GR and inhibit inflammation.  This same idea 
could be used in patients or mouse models.  However, the ratio of ketoconazole to 
glucocorticoid would need to be carefully controlled.  Specifically, dosing would require 
that the CYP3A inhibitor, ketoconazole or a similar agent, be at a high enough 
concentration to effectively inhibit CYP3A enzyme activity, but low enough so that the 
glucocorticoid could outcompete for GR binding, since ketoconazole is also a GR 
antagonist.  Another alternative could be to utilize fluticasone in patients expressing 
CYP3A5*1.  Murai et al. showed that FLT is a potent mechanism-based inactivator of 
CYP3A5, with some inactivation also occurring with CYP3A4 (17).  Thus, patients 






CYP3A enzymes in lung cells, in addition to the intended effect through GR using a 
single drug.  This intriguing concept is supported by the results published by Stockmann 
et al. where it was demonstrated that patients expressing CYP3A4*22, which is associated 
with decreased hepatic CYP3A4 activity, and receiving FLT, showed greater control of 
asthma symptoms than individuals with the CYP3A4*22 genotype who were receiving 
other inhaled glucocorticoids, (with a limited number of subjects receiving drugs other 
than FLT) and compared to patients with the active forms of CYP3A4 (18).  It has also 
been demonstrated that patients who switch to FLT from other glucocorticoids are able to 
manage their asthma symptoms using a lower dose of FLT (19).  Therefore, patients who 
are not showing benefit from glucocorticoid therapy should first be switched to FLT and 
possibly treated with another selective CYP3A enzyme inhibitor, to potentially better treat 
their asthma symptoms.  As such, future studies should aim to confirm the basis of the 
relationship between FLT treatment and metabolic clearance by CYP3A enzymes as a 
possible way to improve how steroid insensitive patients are cared for. 
 In addition to genomic effects of glucocorticoids on GR, there are “off-
target” effects, or nongenomic actions that occur with glucocorticoid treatment.  
Nongenomic actions have a rapid onset, about 90 seconds, and are short in duration (16).  
These effects can be divided into three subcategories, as described by Stahn and Buttgereit 
(20); nonspecific interactions of glucocorticoids with plasma membranes, interaction with 
membrane bound GR, and nongenomic effects through binding to cytosolic GR.  Briefly, 
these nongenomic effects most frequently interfere with mineral and adenosine 
triphosphate transport across plasma membranes, resulting in immune cell suppression 
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(21, 22), inhibit Lck/Fyn kinases, which are downstream from T-cell receptors, and 
suppress major pathways important in T-cell activation (23, 24), or block arachidonic acid 
production, which has been shown to decrease bronchoconstriction and mucus production 
(25, 26).  While these experiments have been shown in vitro, they have not been 
demonstrated in vivo, and more than likely do not play a role in glucocorticoid 
insensitivity due to rapid onset of the effects and short duration (16).   
 Polymorphisms of GR have also been demonstrated and could possibly play a role 
in glucocorticoid insensitivity in asthma patients.  One GR polymorphism, ER22/23EK, 
occurs in 3% of the population and affects exon 2, replacing a lysine with an arginine at 
position 23 (27).  ER22/23EK is associated with lower transcriptional activity by GR in 
reporter assays (28) and has been seen in patients classified as glucocorticoid insensitive 
in other disease states, but not in asthma (29).  More genotyping studies need to be 
completed in asthma patients that respond to glucocorticoid therapy, and those who do 
not, in order to determine if this polymorphism is playing a role in glucocorticoid 
insensitivity in the context of asthma. 
 Esterases play an important role in the bioactivation of BDP and could also play a 
role in glucocorticoid insensitivity.  Esterases can be divided into three classes: A 
esterases, B esterases and C esterases (30, 31).  Those most pertinent to the hydrolysis of 
esterases in the lung are B esterases, which compromise carboxylesterases, 
cholinesterases, and acetycholinesterases, and are serine-dependent enzymes that 
participate in the bioactivation of xenobiotics (32-34).  This class of enzymes has been 
shown to cleave ester groups on a similar glucocorticoid (ciclesonide) to BDP (35) and 
may contribute to activation of BDP in the lung.  It is possible that differences in 
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expression of esterases in the lung, either leading to decreased bioactivation of BDP or 
increased metabolism of BDP, could contribute to glucocorticoid insensitivity, 
independent of CYP3A5 metabolism.  However, glucocorticoid insensitivity occurs with 
all glucocorticoids and most of the glucocorticoids used to treat asthma do not contain 
ester side groups.  Therefore, esterases could only play a role in glucocorticoid 
insensitivity related to certain drugs, not all drugs, as is observed.  As such, a role for 
esterases in glucocorticoid insensitivity is expected to be minimal, if any role at all. 
In summary, the work described in this dissertation supports the over-arching 
hypothesis that individuals who show lower benefit from inhaled glucocorticoid treatment 
may also exhibit increased glucocorticoid metabolism in the lung.  Further work described 
herein should be completed to fully evaluate this interesting possibility in human 
populations, since the elucidation of key factors that affect glucocorticoid efficacy could 
significantly improve the treatment of patients who currently exhibit poor control of 
asthma symptoms with their current inhaled glucocorticoid therapy. 
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